#1Investor Presentation November 15, 2021 R REPLIGEN INSPIRING ADVANCES IN BIOPROCESSING CA 19 8 8 R REPLIGEN OPUS 80R N System (1#2Safe Harbor RREPLIGEN INSPIRING ADVANCES IN BIOPROCESSING This presentation contains forward looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties which may cause our plans to change or actual results to differ materially from those anticipated. In particular, unforeseen events outside of our control may adversely impact future results. Additional information concerning these factors is discussed in our reports filed with the Securities and Exchange Commission including recent Form 8-Ks, our most recent Annual Report on Form 10K and our most recent Quarterly Reports on Form 10Q. The forward looking statements in this presentation reflect management's current views and may become obsolete as a result of new information, future events or otherwise. We may not update such forward looking statements to reflect a change of events or circumstances that occur after the date hereof, except as required by law. The industry and market data contained in this presentation are based on management's own estimates, independent publications, government publications, reports by market research firms or other published independent sources, and, in each case, are believed by management to be reasonable estimates. Although we believe these sources are reliable, we have not independently verified the information. 2#3Repligen Overview Advancing innovation as a trusted partner in the production of biologic drugs R REPLIGEN#4Repligen - A Bioprocessing Innovator Enabling efficient, single-use, high productivity biological drug manufacturing 37% 5-year Revenue CAGR (2015-2020) Consistently above average industry growth $3.7B+ Total Addressable Market An expanding portfolio scaling into clinical and commercial manufacturing Expanding applications Serving multiple biological drug classes Monoclonal antibodies Gene therapy COVID-related vaccines and therapeutics Highly differentiated portfolio through M&A and R&D Advancing disruptive technologies with market leadership positions RREPLIGEN INSPIRING ADVANCES IN BIOPROCESSING 1,465 Employees 530K+ Sq. Ft. Mftg. (6.30.21) Investing in talent, systems & capacity ~500 new employees 9M-21 3 Site Buildouts Ongoing (US, Ireland) 4#5Driving Strong Growth and Performance Delivering novel solutions to biomanufacturing challenges Addressing critical needs of COVID-19 programs Expanding Systems and consumables in Filtration and Chromatography; Building out Process Analytics Business Expanding manufacturing capacity, accelerating hiring 2020 Revenue Splits Analytics Proteins 22% 9% Chroma 20% CORE 83% Filtration 48% COVID 13% M&A 5% Gene Therapy 2020 Highlights $366M TOTAL REVENUE 36% REVENUE GROWTH 29% Organic 57.6% GROSS MARGIN 26.8% ADJ. OPERATING MARGIN $1.65 ADJ. EPS >400 NEW HIRES in 2020 RREPLIGEN INSPIRING ADVANCES IN BIOPROCESSING Guidance 2021* $655M-$665M TOTAL REVENUE 79%-82% REVENUE GROWTH 65%-68% Organic 59%-60% GROSS MARGIN 30%-31% ADJ. OPERATING MARGIN $2.86-$2.91 ADJ. EPS *Guidance as of 10/28/21 earnings call; see Appendix for GAAP to non- GAAP reconciliations LO 5#6Delivering Customer and Shareholder Value Disruptive technologies and expanding markets are driving diversification... 3 DEPLIO G00 Tomer's SAS G EXPOSED LIFT R REPLIGEN XCell ATF 1 LIFT REPLIGEN P REPLIGEN ProConnex TFDF Flow Path Solo $CTECHNOLOGIES, INC. VPE R REPLIGEN OPUS 80R I > Solutions for viral vector, mAb, rPr, vaccine manufacturing ... and increased revenue and profitability Revenue (in $Ms) $800 ** $700 $600 $500 $400 $300 $200 $100 $0 2017-2020 37% 3-year Revenue CAGR $0.58 $141.1 $0.66 $193.9 2.8x increase in Adj. EPS $1.07 R REPLIGEN INSPIRING ADVANCES IN BIOPROCESSING $270.2 $1.65 $366.0 $2.89 $660.0 FY 18* FY 19* FY 17* FY 20 *Change in accounting for the treatment of tax on certain non-GAPP adjustments Adj. EPS is a non-GAAP financial measure; see reconciliations in Appendix *** FY 2021 Guidance at midpoint as of 10/28/21 earnings call *** FY 21G* $3.50 $3.00 $2.50 $2.00 $1.50 $1.00 $0.50 $0.00 Adj. EPS fully diluted ** 6#7Strong Biologics Markets R REPLIGEN#8New and Emerging Markets 2020 Revenue: % of 2020 Revenue: 2021e Revenue: 2021e Incremental: % of 2021 Revenue: Franchise Tailwinds: Where our Products Play: Healthy Biologics Pipeline to Fuel Future Growth: mAbs¹ COVID-19 Vaccines & Therapeutics $46M 13% $175 - $180M (from $46M in 2020) $129 - $134M ~27% Filtration, Chromatography, Proteins Viral vector vaccines rProteins mRNA >120 FDA approved YE 2020 >630 clinical trials Therapeutic mAbs 3 FDA EUA approved YE 2020 >1,500 clinical trials 1. Antibodies to Watch in 2020; MAbs. 2020 Jan-Dec; 12(1): 170353 2. Alliance for Regenerative Medicine Q3 2020 report https://alliancerm.org/sector-report/q3-2020-trend-talk/Deloitte report with references GT CAGR Gene and Cell Therapy R REPLIGEN INSPIRING ADVANCES IN BIOPROCESSING $54M 15% (+30% year-on-year growth) $71 - $76M (+30% -40% year-on year growth) $16 - $22M ~11% Filtration, Chromatography, Process Analytics Plasmids AAV Lentivirus mRNA 9 FDA approved YE 2020 >1,000 clinical trials² 8#9Our Addressable Markets R REPLIGEN#10Our Total Addressable Bioprocessing Market Process Analytics 5%+ market share 2020 growth 25%-30% pro Leader in protein concentration measurement Expanding applications forma Proteins 10%-15% market share ~$630M 2020 organic growth 15%-20% Affinity ligand expertise; leader in Protein A ligands Expanding portfolio ~$575M ~$485M 1. Bioprocessing market expected CAGR of 9% -12% through 2027 SDi Bioprocessing Technologies 2020, May 2020; Grandview Research; Single-use Bioprocessing market 2020-2027 ~$3.7B TAM of >$12B Bioprocessing market¹ ~$2B PREPLIGEN INSPIRING ADVANCES IN BIOPROCESSING Chromatography 15%-20% overall share 2020 organic growth ~15% Leader in pre-packed columns (PPC) OPUS: 50%+ of PPC market PPC market: 40%-50% penetrated 2020 acquisitions account for ~$100M of TAM (ARTESYN) Filtration ~10% share 2020 organic growth 35%+ Leader in upstream clarification, taking share downstream (UF/DF) Winning market share with differentiated technology 2020 acquisitions account for ~$300M of Filtration TAM (EMT, NMS ARTESYN) 10#11Accelerating Growth through M&A and R&D R REPLIGEN#12(0) M&A - Our Strict Acquisition Criteria Technology leadership Strengthens, expands Repligen's presence Underinvested in a key area (commercial, R&D, systems, infrastructure) Strong revenue growth, margins in line with or above corporate average Potential to be accretive to adjusted EPS in first full year post-acquisition Acquisition Refine (assets) Atoll GmbH TangenX Spectrum C Technologies ARTESYN* (+NMS, EMT) Polymem S.A. Avitide Inc. *largest of 3 acquisitions in 2020 Repligen investments in... PREPLIGEN INSPIRING ADVANCES IN BIOPROCESSING Commercial Operations ✓ ✓ ✓ ✓ ✓ R&D ✓ ✓ > ✓ ✓ ✓ Together acquisitions through 2020 contributed >55% of 2020 revenue 12#13Improving on Historical Growth M&A Snapshot 2014-2020 Acquisition year revenue (pro forma) "First full year" revenue growth JUNE 2014 Refine TECHNOLOGY $10.6M 48% Filtration APRIL 2016 * Excluding $4M in sales to Repligen. ** First full year of Repligen ownership, pro forma ATOLL convenience in bioscience $4.6M 26% Chromatography DEC. 2016 TANGENX $5.8M 37% Filtration AUG. 2017 SPECTRUM LABS.COM $37M* 24% Filtration MAY 2019 C TECHNOLOGIES, INC. Flow VPE HE $25.6M RREPLIGEN INSPIRING ADVANCES IN BIOPROCESSING 30% Process Analytics 2020 ARTESYN Engineered BIO-PRODUCTION Technology NMS Molding REPLIGEN Chockgraphy Syn ARTS 229 REPLIGEN >15% Systems/Fluid Management Ⓡ 13#14Recent Acquisition Avitide Inc. September 16, 2021 AVITIDE Technology leader that advances and expands our Proteins franchise to address the unique purification needs of gene therapies and other emerging modalities R REPLIGEN INSPIRING ADVANCES IN BIOPROCESSING Strengthens, expands core ligand discovery & development capabilities with highly differentiated tech Gives Repligen a new best-in-class platform for affinity resin development, with gene therapy focus Complements Navigo GmbH partnership (Protein A/mAb, Spike Protein/COVID focus) and provides affinity content to drive future growth of Proteins franchise Rapid discovery engine with industry best lead times = more content and resins on the market Leverages our commercial and operational expertise and brings content to OPUS®; further strengthens our downstream chromatography portfolio including systems 3 AAV resin commercial launches planned for 2021/2022 Expected to add revenues of ~$10M in 2022, with expected growth >50% in 2023 Expected to be accretive to adjusted EPS and operating margin in 2023 $150M purchase price (50/50 cash/stock) with earnouts based on revenue milestones#15Recent Acquisition Avitide Inc. September 16, 2021 AVITIDE Headquarters: Lebanon, NH Founded: 2013 Co-Founders: Kevin Isett, Ph.D. (CEO), Warren Kett, Ph.D. (CSO), Tillman Gerngross, Ph.D. (Chair) Employees: 40 Manufacturing facilities: Lebanon, NH ISO 9001:2005 certified ● Modular operations for volume flexibility Business Model: ● Combination of custom ligand development for select pharma partners and resin scale-up Moving towards broader reach ligand/resin programs AAV (gene therapy), New modalities >1E14 ligand library diversity >40 unique ligand scaffolds High diversity improves the overall probability of success to identify well-differentiated binders AVITIDE AVITIDE AVITIDE This is a technology play with rapid growth potential $12.0 $10.0 $8.0 $6.0 $4.0 $2.0 $0.0 $2.5M R REPLIGEN INSPIRING ADVANCES IN BIOPROCESSING FY 20 $4.5M (e) FY 21 e $10M (e) FY 22 e Avitide's revenue is expected to double in 2022 and grow >50% in 2023#16Recent Acquisition Polymem SA July 1, 2021 jil PROGR TIT wi Surine Say Showe 2020 % Revenue by Geography Core technology and innovation in hollow fiber membrane and modules (ultra/microfiltration) Immediately increases HF membrane capacity by 3x Creates two customer focus areas within Polymem Industrial and Municipal (Polymem Sales Force) Bioprocessing (Repligen Sales Force) 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Compliments our TFF Systems offerings KrosFlo® HF TFF Systems, ProConnex® Fluid Management, 100% consumables ● 28% 70% Europe US ■ ROW 22% R REPLIGEN INSPIRING ADVANCES IN BIOPROCESSING 78% *excludes any sales to Repligen Castanet-Tolosan, France polymem MEMBRANE MANUFACTURER 2021 Revenue est. ~$7M* Life Sciences/Hospital OEM Industrial/Municipal 0#17Advancing Growth through R&D, Partnerships First to market with innovative solutions 11 N R REPLIGEN L OPUS 80R OPUS® R Pre-packed Columns Key Partnerships LIFT R REPLIGEN XCell ATF LIFT REPLIGEN 8 XCell ATFⓇ Single-use Systems Navigo Proteins PURE PRECISION Affinity ligands Clas REPLIGEN KrosFloⓇ Systems Single-use (HF TFF, FS TFF, TFDF) Purolite® Protein A resins REPLIGEN ***.. ... PEPLIGEN ngen 35, Camma EXPOSED TangenX® SIUSⓇ Single-use Flat Sheet TFF sartorius stedim biotech Integrated perfusion bioreactors Flow VPE 1:31 RREPLIGEN INSPIRING ADVANCES IN BIOPROCESSING Sole FlowVPEⓇ and SoloVPEⓇ VPE PI REPLISER ProConnes TFDF Fl Of Flow Park KrosFloⓇ TFDF 17